Xponance Inc. Reduces Stock Position in Insulet Co. (NASDAQ:PODD)

Xponance Inc. trimmed its holdings in Insulet Co. (NASDAQ:PODD) by 1.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,566 shares of the medical instruments supplier’s stock after selling 158 shares during the period. Xponance Inc.’s holdings in Insulet were worth $4,064,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of PODD. Intech Investment Management LLC grew its position in shares of Insulet by 219.4% in the fourth quarter. Intech Investment Management LLC now owns 3,073 shares of the medical instruments supplier’s stock valued at $802,000 after purchasing an additional 2,111 shares in the last quarter. Generali Asset Management SPA SGR bought a new position in Insulet in the 4th quarter worth about $3,264,000. Horizon Investments LLC grew its holdings in Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after buying an additional 42 shares in the last quarter. Counterpoint Mutual Funds LLC bought a new stake in shares of Insulet during the fourth quarter valued at about $297,000. Finally, Cibc World Markets Corp lifted its holdings in shares of Insulet by 46.1% in the fourth quarter. Cibc World Markets Corp now owns 13,851 shares of the medical instruments supplier’s stock worth $3,616,000 after buying an additional 4,368 shares in the last quarter.

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.47% of the company’s stock.

Insulet Price Performance

PODD opened at $265.39 on Friday. The stock’s 50 day simple moving average is $272.11 and its 200 day simple moving average is $256.26. The firm has a market cap of $18.64 billion, a price-to-earnings ratio of 45.84, a PEG ratio of 3.62 and a beta of 1.29. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. As a group, analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on PODD shares. Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price on the stock. Stifel Nicolaus upped their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Raymond James reissued an “outperform” rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. TD Cowen upped their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Finally, Wells Fargo & Company lifted their price target on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.